Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition
Marcin P. Iwanicki, … , Ronny Drapkin, Joan S. Brugge
Marcin P. Iwanicki, … , Ronny Drapkin, Joan S. Brugge
Published July 7, 2016
Citation Information: JCI Insight. 2016;1(10):e86829. https://doi.org/10.1172/jci.insight.86829.
View: Text | PDF
Research Article Cell biology Oncology

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition

  • Text
  • PDF
Abstract

High-grade serous ovarian carcinoma (HGS-OvCa) harbors p53 mutations and can originate from the epithelial cell compartment of the fallopian tube fimbriae. From this site, neoplastic cells detach, survive in the peritoneal cavity, and form cellular clusters that intercalate into the mesothelium to form ovarian and peritoneal masses. To examine the contribution of mutant p53 to phenotypic alterations associated with HGS-OvCA, we developed live-cell microscopy assays that recapitulate these early events in cultured fallopian tube nonciliated epithelial (FNE) cells. Expression of stabilizing mutant variants of p53, but not depletion of endogenous wild-type p53, in FNE cells promoted survival and cell-cell aggregation under conditions of cell detachment, leading to the formation of cell clusters with mesothelium-intercalation capacity. Mutant p53R175H-induced phenotypes were dependent on fibronectin production, α5β1 fibronectin receptor engagement, and TWIST1 expression. These results indicate that FNE cells expressing stabilizing p53 mutants acquire anchorage independence and subsequent mesothelial intercalation capacity through a mechanism involving mesenchymal transition and matrix production. These findings provide important new insights into activities of mutant p53 in the cells of origin of HGS-OvCa.

Authors

Marcin P. Iwanicki, Hsing-Yu Chen, Claudia Iavarone, Ioannis K. Zervantonakis, Taru Muranen, Marián Novak, Tan A. Ince, Ronny Drapkin, Joan S. Brugge

×

Figure 5

Integrin α5β1 supports mutant p53 (m-p53)–induced survival under detached conditions.

Options: View larger image (or click on image) Download as PowerPoint
Integrin α5β1 supports mutant p53 (m-p53)–induced survival under detache...
(A) Upper panel: Western blots of integrin α5, integrin β1, p53, and actin expression in the various fallopian tube nonciliated epithelial (FNE) cell lines. Three independent experiments were performed. Lower panel: Representative video clips (n = 5/condition) of FNE-m-p53R175H or DF30 cell clusters treated with the indicated function-blocking Abs and cultured in serum/EGF-free medium in suspension for 24 hours (Supplemental Video 9, A and B). Arrows point to dying cells. Five movies were recorded per cell type with 100–150 cells per movie. Scale bar: 150 μm. (B) Representative (n = 15) pseudocolored fluorescence images of ethidium bromide (EtBr) incorporation into GFP-labeled FNE-m-p53R175H cell clusters treated with the indicated function-blocking Abs and cultured in serum/EGF-free medium for 48 hours. Scale bar: 100 μm. (C) Quantification of EtBr incorporation into FNE-mp53R175H cell clusters cultured in suspension in serum/EGF-free media in the presence of the indicated function-blocking Abs at the indicated concentrations. This experiment was repeated 3 times at the 2.7 μg/ml concentration of integrin function–blocking Abs and at the 4 μg/ml of mucin 16 (MUC16)– or N-cadherin–blocking Abs, with n = 5 cell clusters scored per condition. Each cell cluster consisted of 100–150 cells. (D) Representative (n = 15) pseudocolored fluorescence images of EtBr incorporation into GFP-labeled DF30 cell clusters treated with the indicated concentration of function-blocking Abs and cultured in serum/EGF-free medium in suspension for 48 hours. Scale bar: 100 μm. (E) Quantification of EtBr incorporation into DF30 cell clusters treated with function-blocking Abs at the indicated concentrations and cultured in suspension in serum/EGF-free media for 48 hours. This experiment was repeated 3 times at the 1.4 μg/ml concentration of integrin-blocking Abs and at the 4 μg/ml of mucin 16 (MUC16)– or N-cadherin–blocking Abs with n = 5 cell clusters analyzed per condition. Each cell cluster consisted of 100–150 cells. All data shown as the median (horizontal bar), interquartile range (box), and minimum/maximum values (whiskers). *P < 0.05 for each condition relative to the samples treated with MUC16 Ab determined by a 1-way ANOVA and post-hoc Tukey-Kramer test comparing each condition to the MUC16 control. NS, not significant difference relative to the MUC16 control.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts